‘We probably would have had a 95% refusal rate’ for these shots two years ago, but the pandemic and marketing of the injections as ‘vaccines’ has made them popular with the public, said Stefan Oelrich.
The president of Bayer’s Pharmaceuticals Division told international “experts” during a globalist health conference that the mRNA COVID-19 shots are indeed “cell and gene therapy” marketed as “vaccines” to be palatable to the public.
Stefan Oelrich, president of Bayer’s Pharmaceuticals Division, made these comments at this year’s World Health Summit, which took place in Berlin from October 24-26 and hosted 6,000 people from 120 countries. Oelrich told his fellow international “experts” from academia, politics, and the private sector that the novel mRNA COVID “vaccines” are actually “cell and gene therapy” that would have otherwise been rejected by the public if not for a “pandemic” and favorable marketing.
“We are really taking that leap [to drive innovation] – us as a company, Bayer – in cell and gene therapies … ultimately the mRNA vaccines are an example for that cell and gene therapy. I always like to say: if we had surveyed two years ago in the public – ‘would you be willing to take a gene or cell therapy and inject it into your body?’ – we probably would have had a 95% refusal rate,” stated Oelrich.
“Our successes over these 18 months [the duration of the COVID ‘pandemic’] should embolden us to fully focus much more closely on access, innovation and collaboration to unleash health for all, especially as we enter, on top of everything else that is happening, a new era of science – a lot of people talk about the Bio Revolution in this context,” continued the businessman.
According to the McKinsey Global Institute, the “Bio Revolution” is “a confluence of advances in biological science and accelerating development of computing, automation, and artificial intelligence [that] is fueling a new wave of innovation. This Bio Revolution could have significant impact on economies and our lives, from health and agriculture to consumer goods, and energy and materials.”